• A pulse radiolysis study of the complexing of furocoumarins with DNA and proteins.

      Beaumont, P C; Land, Edward J; Navaratnam, S; Parsons, B J; Phillips, G O; Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, England (1980-06-27)
      The complexing of furocoumarins with DNA in aqueous solution has been investigated using the fast-reaction technique of pulse radiolysis. Association constants are given for 8-methoxypsoralen, psoralen, khellin, angelicin, 5,7-dimethoxycoumarin, 5-methoxypsoralen and 4'-aminomethyl-4,5',8-trimethylpsoralen. In addition, the complexing of some furocoumarins to the protein, bovine serum albumin, has also been studied.
    • Pulse radiolytic and electrochemical investigations of intramolecular electron transfer in carotenoporphyrins and carotenoporphyrin-quinone triads

      Land, Edward J; Lexa, D; Bensasson, R V; Gust, D; Moore, T A; Moore, A L; Liddell, P A; Nemeth, G A; Paterson Institute for Cancer Research, CHristie Hospital and Holt Radium Institute, Manchester M20 9BX, U.K. (1987)
    • Pulse-radiolysis study of a biological matrix.

      Cercek, B; Cercek, L; Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester (1973-08)
    • Pulse-radiolysis study of the effect of pH on the one-electron reduction potentials of lumichrome derivatives

      Heelis, P; Parsons, B; Phillips, G; Land, Edward J; Swallow, A John; Research Division, North East Wales Institute, Deeside, Clwyd CH5 4BR (1985)
    • Pulsed irradiation of water soluble porphyrins

      Bonnet, R; Ridge, R J; Land, Edward J; Sinclair, R S; Tait, D; Truscott, T G (1982)
    • Pulsed irradiation studies of some reactive intermediates of melanogenesis

      Land, Edward J; Paterson Institute for Cancer Research Christie Hospital & Holt Radium Institute Manchester M20 9BX, England, UK (1988)
    • Pulsed radiation studies of photodynamic sensitisers: the nature of DHE.

      Keir, W F; Land, Edward J; MacLennan, A H; McGarvey, D J; Truscott, T G; Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, M200 9BX, England, UK (1987-11)
    • Pulsed ultrasound measurements of depth and regression of basal cell carcinomas after photodynamic therapy: relationship to probability of 1-year local control.

      Moore, James V; Allan, Ernest; Laser Oncology Group, Paterson Institute for Cancer Research, Christie Hospital (NHS) Trust, Manchester M20 4BX, UK. jmoore@picr.man.ac.uk (2003-11)
      BACKGROUND: The regression of clinical basal cell carcinoma (BCC) after photodynamic therapy (PDT) is poorly understood, but is potentially important when, as is increasingly the case, a second treatment is contemplated. High-frequency pulsed ultrasound provides noninvasive information on skin and lesion thickness. OBJECTIVES: To relate pulsed ultrasound measurements before and after PDT to the probability of local control of BCC by PDT. METHODS: Skin thickness and lesion thickness were measured by 20-MHz pulsed ultrasound in 181 patients diagnosed as having BCC. Maximal lesion thickness was determined by repeatedly sampling the BCCs. Measurements were made immediately prior to PDT with aminolaevulinic acid plus 630 nm visible light, and then at 1, 6 and 12 months. RESULTS: Skin thickness in individual patients did not vary with time in this study (mean +/- SD 2.3 +/- 0.6 mm; P = 0.8). In contrast, BCC mean +/- SD maximal thickness 4-6 weeks after PDT was significantly smaller than pretreatment (0.6 +/- 0.8 mm vs. 1.3 +/- 0.8 mm; P < 0.001). The overall probability of 1-year local control fell from 85% when only BCCs
    • Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.

      Madej, Monika; Conway, Margaret J; Morgan, A J; Sweet, J; Wallace, L; Qualtiere, L F; Arrand, John R; Mackett, Mike; Department of Molecular Biology, Paterson Institute for Cancer Research, Manchester, UK. (1992)
      Our initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases.
    • Purification and partial characterization of the major cell-associated heparan sulphate proteoglycan of rat liver.

      Lyon, Malcolm; Gallagher, John T; Cancer Research Campaign Department of Medical Oncology, Christie Hospital, Manchester, U.K. (1991-01-15)
      Heparan sulphate proteoglycans were solubilized from whole rat livers by homogenization and dissociative extraction with 4 M-guanidinium chloride containing Triton X-100 and proteinase inhibitors. The extract was subjected to trichloroacetic acid precipitation and the proteoglycan remained soluble. This was then purified to apparent homogeneity by a combination of (a) DEAE-Sephacel chromatography, (b) digestion with chondroitinase ABC followed by f.p.l.c. Mono Q ion-exchange chromatography, and (c) density-gradient centrifugation in CsCl and 4 M-guanidinium chloride. Approx. 1.5 mg of proteoglycan was obtained from 30 livers with an estimated recovery of 25%. The purified proteoglycan was eluted from Sepharose CL6B as an apparently single polydisperse population with a Kav. of 0.19 and displayed a molecular mass of greater than or equal to 200 kDa (relative to protein standards) by SDS/PAGE. Its heparan sulphate chains were eluted with a Kav. of 0.44 and have an estimated molecular mass of 25 kDa. Digestion of the proteoglycan with a combination of heparinases yielded core proteins of 77, 49 and 44 kDa. Deglycosylation using trifluoromethanesulphonic acid, though slightly decreasing the sizes, gave an identical pattern of core proteins. Electrophoretic detergent blotting demonstrated that all of the core proteins were hydrophobic and are probably integral plasma membrane molecules. The peptide maps generated by V8 proteinase digestion of the two major core proteins (77 and 49 kDa) were very similar, suggesting that these two core proteins are structurally related.
    • Purification of aplastic anaemia (AA) marrow haemopoietic progenitors combined with long-term marrow cultures (LTMC) to assess haemopoiesis in AA.

      Marsh, Judith C W; Chang, James; Testa, Nydia G; Hows, J M; Dexter, T Michael; Department of Experimental Haematology, Paterson Institute, Christie Hospital, Manchester, UK. (1991)
    • Purification of haemopoietic stem cells--the end of the road?

      Lord, Brian I; Dexter, T Michael; Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Wilmlsow Road, Manchester M20 9BX, UK (1988-12)
    • Purification of the E. coli ogt gene product to homogeneity and its rate of action on O6-methylguanine, O6-ethylguanine and O4-methylthymine in dodecadeoxyribonucleotides.

      Wilkinson, M C; Potter, P M; Cawkwell, L; Georgiadis, P; Patel, D; Swann, P F; Margison, Geoffrey P; Department of Carcinogenesis, Christie Hospital and Holt Radium Institute, Manchester, UK. (1989-11-11)
      The E. coli gene ogt encodes the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (O6-AlkG ATase). The protein coding region of the gene was cloned into a multicopy expression vector to obtain high yields of the enzyme (approximately 0.2% of total protein) which was purified to apparent homogeneity by affinity, molecular exclusion and reverse-phase chromatography. Good correlation was found between the determined and predicted amino acid compositions. The ability of the purified protein to act on O6-methylguanine (O6-MeG), O6-ethylguanine (O6-EtG) and O4-methylthymine (O4-MeT) in self-complementary dodecadeoxyribonucleotides was compared to that of 19 kDa fragment of the related ada-protein. With both proteins the rate order was O6-MeG greater than O6-EtG greater than O4-MeT, however, the ogt protein was found to repair O6-MeG, O6-EtG and O4-Met, 1.1, 173 and 84 times, respectively, faster than the ada protein.
    • Purification to apparent homogeneity and partial amino acid sequence of rat liver O6-alkylguanine-DNA-alkyltransferase.

      Wilkinson, M C; Cooper, Donald P; Southan, C; Potter, P M; Margison, Geoffrey P; Department of Carcinogenesis, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK. (1990-01-11)
      O6-alkylguanine-DNA-alkyltransferase (ATase) activity was increased in rat liver from 80 to 320 fmoles/mg total protein 48 h after administration of 2-acetylaminofluorene at 60 mg/kg body weight. This tissue was used as a source of ATase which was purified by ammonium sulphate precipitation and DNA-cellulose, molecular exclusion and ion exchange chromatography (IEC). IEC purified material showed a major 24 kDa band after polyacrylamide gel electrophoresis (PAGE) with silver staining. Fluorography of purified ATase following incubation with [3H]-methylated substrate DNA and PAGE showed a single band at 24 kDa suggesting that, as with bacterial ATases, the protein itself accepts the alkyl group from O6-alkylguanine in substrate DNA during the repair reaction. Further purification of the protein using reverse phase HPLC resulted in a single peak representing approximately 125,000 fold purification. This was subjected to amino-terminal sequencing and it was found that the protein was blocked at the amino-terminal end: it was cleaved using trypsin or cyanogen bromide and the amino acid sequence of several reverse phase HPLC purified fragments was determined.
    • Purified tumour angiogenesis factor enhances proliferation of capillary, but not aortic, endothelial cells in vitro.

      Keegan, A; Hill, C; Kumar, Shant; Phillips, P; Schor, Ana M; Weiss, J; Christie Hospital, Manchester, M13 9PL, UK (1982-06)
      Purified tumour angiogenesis factor (TAF) obtained from rat Walker 256 carcinoma and found to induce neovascularization in vivo was examined for its effect on endothelial cell cultures of capillary (CBEC), cow aorta (CAEC) and pig aorta (PAEC) in vitro. Treatment with TAF increased the growth of capillary but not aortic endothelial cells, and then only when the cells were growing on a native collagen substratum. These data show an important growth difference between endothelial cells, in that the ability to proliferate in response to TAF depends not only on the substratum used but also on the vascular origin of the cells.
    • A putative human breast stem cell population is enriched for steroid receptor-positive cells.

      Clarke, Robert B; Spence, Katherine; Anderson, Elizabeth; Howell, Anthony; Okano, Hideyuki; Potten, Christopher S; Breast Biology Group, Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital (NHS) Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK. rclarke@picr.man.ac.uk (2005-01-15)
      Breast epithelial stem cells are thought to be the primary targets in the etiology of breast cancer. Since breast cancers mostly express estrogen and progesterone receptor (ERalpha and PR), we examined the biology of these ERalpha/PR-positive cells and their relationship to stem cells in normal human breast epithelium. We employed several complementary approaches to identify putative stem cell markers, to characterise an isolated stem cell population and to relate these to cells expressing the steroid receptors ERalpha and PR. Using DNA radiolabelling in human tissue implanted into athymic nude mice, a population of label-retaining cells were shown to be enriched for the putative stem cell markers p21(CIP1) and Msi-1, the human homolog of Drosophila Musashi. Steroid receptor-positive cells were found to co-express these stem cell markers together with cytokeratin 19, another putative stem cell marker in the breast. Human breast epithelial cells with Hoechst dye-effluxing "side population" (SP) properties characteristic of mammary stem cells in mice were demonstrated to be undifferentiated "intermediate" cells by lack of expression of myoepithelial and luminal apical membrane markers. These SP cells were 6-fold enriched for ERalpha-positive cells and expressed several fold higher levels of the ERalpha, p21(CIP1) and Msi1 genes than non-SP cells. In contrast to non-SP cells, SP cells formed branching structures in matrigel which included cells of both luminal and myoepithelial lineages. The data suggest a model where scattered steroid receptor-positive cells are stem cells that self-renew through asymmetric cell division and generate patches of transit amplifying and differentiated cells.
    • Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model.

      Bach, Simon P; Chinery, Rebecca; O'Dwyer, Sarah T; Potten, Christopher S; Coffey, Robert J; Watson, Alastair; Cancer Research Campaign, Department of Epithelial Biology, The Paterson Institute, Manchester, England. (2000-01)
      BACKGROUND & AIMS: The thiol-containing antioxidant pyrrolidinedithiocarbamate (PDTC) enhances the cytotoxic efficacy of 5-fluorouracil (5-FU) against human colorectal cancer cell lines in vitro and in vivo. This process appears to be mediated by a sustained increase in p21 expression, independent of p53 function, resulting in growth arrest and apoptosis. We determined whether PDTC augmented 5-FU intestinal toxicity in non-tumor-bearing mice. METHODS: Apoptotic and mitotic indices were measured in the small and large intestine on a cell positional basis at intervals throughout the 72-hour period after administration of 5-FU (40 mg/kg) and PDTC (250 mg/kg). The proportion of crypts regenerating after 5-FU (600-1200 mg/kg) and PDTC (500 mg/kg) was also measured. RESULTS: 5-FU therapy induces substantial apoptotic cell death with simultaneous inhibition of mitotic activity within the small and large intestinal epithelium. PDTC reduces 5-FU-induced apoptotic events in the colon by 49%, predominantly among clonogenic stem and transit cells while promoting the early recovery of mitotic activity. As a consequence, PDTC increased the proportion of regenerating colonic crypts after 5-FU therapy. PDTC did not, however, significantly modulate 5-FU toxicity in the small intestine. CONCLUSIONS: PDTC does not augment the intestinal toxicity of 5-FU and actually protects the colonic mucosa. These results support further investigation of PDTC and related compounds as treatments for colorectal cancer.
    • Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma

      Cummings, Jeffrey; Ranson, Malcolm R; Butt, Fouziah; Moore, David; Dive, Caroline; Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, England. jcummings@picr.man.ac.uk (2007-11)
      PURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.
    • Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2 - A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements

      Valle, Juan W; Hollebecque, A.; Furuse, J.; Goyal, L.; Meric-Bernstam, F.; Morlock, R.; He, Y.; Benhadji, K.; Bridgewater, J.; Division of Cancer Sciences, University of Manchester/The Christie NHS Foundation Trust, Manchester, (2020)
      Background: Cancer treatment can produce AEs that result in a reduced QoL. Futibatinib, a highly selective irreversible FGFR1e4 inhibitor, demonstrated an objective response rate (ORR) of 37.3% and median 8.3-mo duration of response in the interim analysis of FOENIX-CCA2, a mutlicenter phase II trial of pts with advanced, refractory iCCA harboring an FGFR2 fusion/rearrangement; grade 3 treatment-related AEs (TRAEs) occurred in 57% of pts (most commonly, hyperphosphatemia [26.9%]). Change in pt-reported outcomes (PROs) from baseline (BL) for the interim data of the phase II trial are presented here. Methods: Pts enrolled into FOENIX-CCA2 (NCT02052778), had locally advanced/ metastatic unresectable iCCA and received oral futibatinib 20 mg once daily (QD) until disease progression/intolerance. PRO measures included EORTC-QLQ-C30 (5 functional and 9 physical measures) and EQ-5D-3L (utility index and 5 dimensions: anxiety/ depression, mobility, pain/discomfort, self-care, and usual activity). PROs were collected at screening, cycles 2 and 4, every 3 cycles after cycle 4 and at the end of treatment. Change in mean score from BL was assessed using predefined clinically meaningful thresholds for each time point with 19 observations (through cycle 13). Results: Sixty-seven of 103 enrolled pts had 6 months of follow-up and 57 (85.1%) had PRO completion data at BL and 1 assessment. EORTC mean global health status score was high at BL (68.7) and maintained through cycle 13 (70.8), a trend observed across all EORTC measures. The only clinically meaningful changes ( 10-point changes) in this timeframe were for constipation symptoms at cycles 2 and 4 (worsened +12.4 and +10.7, respectively) and dyspnea at cycle 10 (improved -12.2). Mean EQ-5D-3L index scores improved from 70.9 at BL to 79.1 at cycle 13 (approximately 273 days on treatment). Conclusions: Overall, the interim PROs from FOENIX-CCA2 were encouraging. These data suggest that despite the occurrence of TRAEs, a 20-mg-QD dose of futibatinib in pts with iCCA provides a promising clinical response without adversely impacting QoL.